Hemab Therapeutics

📍 Copenhagen, Denmark🗓 Founded 2019👥 23 employees💰 Last funded 2021
Biotechnology Research🌐 hemab.com
Website LinkedIn
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Hemab Therapeutics?
Hemab Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Hemab Therapeutics last raise funding?
The most recent investment in Hemab Therapeutics recorded on gritt.io was in 2021.
When was Hemab Therapeutics founded?
Hemab Therapeutics was founded in 2019.
What industry is Hemab Therapeutics in?
Hemab Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Hemab Therapeutics based?
Hemab Therapeutics is headquartered in Copenhagen, Denmark.